Pfizer Acquires Seagen for $43B and Accelerates Oncology Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Fool
- Oncology Expansion: Pfizer's $43 billion acquisition of Seagen enhances its access to a substantial pipeline of investigational cancer therapies, which could significantly boost its competitive position in the global oncology market and potentially yield financial returns by 2026.
- Drug Development Progress: The acceleration of PF-08634404, licensed from 3SBio, includes multiple clinical trials, with expected clinical progress reports next year, which will positively impact Pfizer's long-term strategy, especially in competing against Keytruda in key markets.
- Weight Management Initiatives: Pfizer is developing several anti-obesity candidates, including PF-07976016 and MET-097i, the latter showing promising results in phase 2 trials and expected to enter phase 3 next year, potentially opening new revenue streams and enhancing market positioning.
- 2026 Financial Guidance: Pfizer projects revenue between $59.5 billion and $62.5 billion for 2026, indicating a slight decrease from 2025, but despite challenges in its COVID-19 vaccine sales, the promising pipeline could improve financial outcomes in the coming years.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
10 Hold
1 Sell
Hold
Current: 24.900
Low
24.00
Averages
29.08
High
34.00
Current: 24.900
Low
24.00
Averages
29.08
High
34.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
